AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2015
Feb 19, 2015
33148_dirs_2015-02-18_aab38dca-84e5-4053-8b7d-c1957fce0086.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2015-02-17
Reporting Person: HOWES PAUL G (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series X Convertible Preferred Stock | $ | Common Stock (101489) | Direct | ||
| Stock Options (right to buy) | $40.578 | 2018-08-31 | Common Stock (6160) | Direct | |
| Stock Options (right to buy) | $4.342 | 2024-08-28 | Common Stock (9857) | Direct |
Footnotes
F1: The Series X Convertible Preferred Stock ("Series X Preferred") is convertible at any time at the holder's election and has no expiration date. All shares of Series X Preferred, including all accrued and unpaid dividends thereon, will be automatically converted on a 4.05783-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. The number of shares of Common Stock as shown in column 3 is based on a conversion of 509,837 shares of Series X Preferred.
F2: These options are fully vested.